Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

61. [Notice of the impact of the decrease of the maximum payable amount for the class of proton pump inhibitors]

[Notice of the impact of the decrease of the maximum payable amount for the class of proton pump inhibitors] Avis sur l'impact de la baisse du prix maximal payable sur la classe des inhibiteurs de la pompe à protons [Notice of the impact of the decrease of the maximum payable amount for the class of proton pump inhibitors] Avis sur l'impact de la baisse du prix maximal payable sur la classe des inhibiteurs de la pompe à protons [Notice of the impact of the decrease of the maximum payable amount (...) for the class of proton pump inhibitors] Jehanno C, Robitaille J, Bouchard S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jehanno C, Robitaille J, Bouchard S. Avis sur l'impact de la baisse du prix maximal payable sur la classe des inhibiteurs de la pompe à protons. [Notice of the impact of the decrease of the maximum payable amount for the class

2015 Health Technology Assessment (HTA) Database.

62. Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus

Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus Proton pump inhibitors (PPIs) are associated with very infrequent cases of subacute cutaneous lupus erythematosus (SCLE), a non-scarring dermatosis that can develop in sun-exposed areas (...) . Published 8 September 2015 From: Therapeutic area: , Contents If a patient treated with a proton pump inhibitor ( Proton pump inhibitors A review of medical records of patients at a dermatology unit in a university hospital in Denmark identified 19 cases of A further 17 cases of Cumulatively, of the cases reviewed from literature and from case reports submitted by Sandholdt LH and others. Proton pump inhibitor-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2014; 170: 342–51. Almebayadh M

2015 MHRA Drug Safety Update

63. Proton Pump Inhibitors for Gastrointestinal Conditions

Proton Pump Inhibitors for Gastrointestinal Conditions Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along (...) . It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Proton Pump Inhibitors for Gastrointestinal Conditions: A Review

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

64. Proton Pump Inhibitors in Upper GI Bleeds

Proton Pump Inhibitors in Upper GI Bleeds Emergency Medicine > Journal Club > Archive > August 2015 Toggle navigation August 2015 Proton Pump Inhibitors in Upper GI Bleeds Vignette You're working a shift in EM-­‐2 one day when you pick up a patient with the chief\ complaint of "bloody emesis." The patient is a 45 year old male with a history of chronic low back pain who takes daily naproxen (250 mg BID). His pain worsened two months ago when he was in an MVC, and he has been taking ibuprofen (...) PT/INR and PTT are normal. An NG tube is placed and returns coffee grounds with streaks of blood that do not clear after lavage with one liter of normal saline. You order a type and screen and cross him for 4 units (just incase). You call the GI fellow, thinking that the patient probably needs an upper endoscopy. The GI fellow asks that you start the patient on a continuous infusion of intravenous antoprazole. You wonder how useful IV proton pump inhibitors actually are in the setting of upper GI

2015 Washington University Emergency Medicine Journal Club

65. Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up

Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up Suivi de la mesure de remboursement des inhibiteurs de la pompe à protons (IPP) [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up] Suivi de la mesure de remboursement des inhibiteurs de la pompe à protons (IPP) [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up] Régie de l'assurance maladie du Québec, Jehanno C, Baril J, Chamberland C Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Régie de l'assurance maladie du Québec, Jehanno C, Baril J, Chamberland C. Suivi de la mesure de remboursement des inhibiteurs de la pompe à protons (IPP). [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2014 Authors

2014 Health Technology Assessment (HTA) Database.

66. Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients: A Systematic Review and Meta-Analysis

Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients: A Systematic Review and Meta-Analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2014 PedsCCM Evidence-Based Journal Club

67. Proton Pump Inhibitors: Acid Suppression with a Nutritional Cost

Proton Pump Inhibitors: Acid Suppression with a Nutritional Cost Proton Pump Inhibitors: Acid Suppression with a Nutritional Cost – Clinical Correlations Search Proton Pump Inhibitors: Acid Suppression with a Nutritional Cost June 13, 2014 5 min read By Dana Zalkin Peer Reviewed In the late 1970s evidence began to emerge that a newly discovered pump, [1]. With this discovery, further research [2]. We now have drugs that do just that: the proton pump inhibitors (PPIs). Proton pump inhibitors (...) Nutr. 1997;66(4):750-759. 7. Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. Annu Rev Nutr. 1999;19:357-377. 8. Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9(3):162-167. doi: 10.1016/j.jamda.2007.10.004. 9. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol

2014 Clinical Correlations

68. Proton Pump Inhibitors and Clostridium Difficile Infection

Proton Pump Inhibitors and Clostridium Difficile Infection Proton Pump Inhibitors and Clostridium Difficile Infection – Clinical Correlations Search Proton Pump Inhibitors and Clostridium Difficile Infection March 20, 2014 4 min read By Aaron Smith, MD Peer Reviewed First introduced in the late 1980s, proton pump inhibitors (PPIs) have revolutionized the treatment of gastric acid-related disorders and have been described as a miracle drug by patients and physicians alike. As is often the case (...) al. Nosocomial Clostridium difficile colonisation and disease. Lancet. 1990;336(8707):97–100. [3] [4] Gurian L, Ward TT, Katon RM. Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium difficile: influence of gastrointestinal secretions on Clostridium difficile infection. Gastroenterology. 1982;83(2):465-469. [5] Kaur S, Vaishnavi C, Prasad KK, Ray P, Kochhar R. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile

2014 Clinical Correlations

69. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis

Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis Alhazzani W, Alenezi F (...) , Jaeschke RZ, Moayyedi P, Cook DJ CRD summary The review concluded that, in critically ill patients, proton pump inhibitors seemed more effective than histamine 2 receptor antagonists in preventing clinically important and overt upper gastrointestinal bleeding, but limitations in the evidence mean that these findings should not be considered as being robust. The authors' conclusions are likely to be reliable. Authors' objectives To determine the efficacy and safety of proton pump inhibitors compared

2014 DARE.

70. Histamine-2 Receptor Antagonists vs Proton Pump Inhibitors on Gastrointestinal Tract Hemorrhage and Infectious Complications in the Intensive Care Unit (Full text)

Histamine-2 Receptor Antagonists vs Proton Pump Inhibitors on Gastrointestinal Tract Hemorrhage and Infectious Complications in the Intensive Care Unit IMPORTANCE Histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) are commonly used to prevent gastrointestinal tract (GI) hemorrhage in critically ill patients. The stronger acid suppression of PPIs may reduce the rate of bleeding but enhance infectious complications, specifically pneumonia and Clostridium difficile (...) %; P < .001) occurred less frequently in the H2RA group. After adjusting for propensity score and covariates, odds ratios of GI hemorrhage (2.24; 95% CI, 1.81-2.76), pneumonia (1.2; 95% CI, 1.03-1.41), and CDI (1.29; 95% CI, 1.04-1.64) were greater with PPIs. Similar results were obtained in the propensity-matched models of 8799 patients in each cohort. CONCLUSIONS AND RELEVANCE Proton pump inhibitors are associated with greater risks of GI hemorrhage, pneumonia, and CDI than H2RAs

2014 EvidenceUpdates PubMed

71. [Notice on the reimbursement of proton pump inhibitors]

[Notice on the reimbursement of proton pump inhibitors] Avis sur le remboursement des inhibiteurs de la pompe à protons [Notice on the reimbursement of proton pump inhibitors] Avis sur le remboursement des inhibiteurs de la pompe à protons [Notice on the reimbursement of proton pump inhibitors] Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Avis sur le remboursement des inhibiteurs de la pompe à protons . [Notice on the reimbursement of proton pump inhibitors] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). ETMIS; 9(2). 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Proton Pump Inhibitors Language Published French Country of organisation Canada Province or state Quebec English summary An English language summary is available. Address for correspondence

2014 Health Technology Assessment (HTA) Database.

72. Randomised controlled trial: For proton pump inhibitor-dependent gastro-oesophageal reflux, laparoscopic fundoplication is superior to medical therapy at 5?years of follow-up

Randomised controlled trial: For proton pump inhibitor-dependent gastro-oesophageal reflux, laparoscopic fundoplication is superior to medical therapy at 5?years of follow-up For proton pump inhibitor-dependent gastro-oesophageal reflux, laparoscopic fundoplication is superior to medical therapy at 5 years of follow-up | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any (...) time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here For proton pump inhibitor-dependent gastro-oesophageal reflux

2014 Evidence-Based Medicine (Requires free registration)

73. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. (Full text)

Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. Proton pump inhibitors (PPIs) and histamine 2 receptor antagonists (H2RAs) suppress the production of gastric acid and thus may lead to malabsorption of vitamin B12. However, few data exist regarding the associations between long-term exposure to these medications and vitamin B12 deficiency in large population-based studies.To study the association between use of PPIs and H2RAs and vitamin B12 deficiency (...) less than 0.75 pills/d (OR, 1.63 [95% CI, 1.48-1.78]; P = .007 for interaction).Previous and current gastric acid inhibitor use was significantly associated with the presence of vitamin B12 deficiency. These findings should be considered when balancing the risks and benefits of using these medications.

2013 JAMA PubMed

74. Canadian Association of Gastroenterology position statement: Hip fracture and proton pump inhibitor therapy ? a 2013 update

Canadian Association of Gastroenterology position statement: Hip fracture and proton pump inhibitor therapy ? a 2013 update CANADIAN ASSOCIATION OF GASTROENTEROLOGY L’ASSOCIATION CANADIENNE DE GASTROENTEROLOGIE CAG/ACG National Office, 224 – 1540 Cornwall Road, Oakville, ON, Canada L6J 7W5 Telephone: 905.829.2504 Toll free: 1.888.780.0007 Fax: 905.829.0242 E-mail: CAGOffice@cag-acg.org Website: http://www.cag-acg.org CAG Position Statement: Hip fracture and proton pump inhibitor therapy (...) – a 2013 update Paul Moayyedi, Bsc, MB ChB, PhD, MPH, FRCP, FRCPC, AGAF, FACG Yuhong Yuan, MSc, MD, PhD Grigorios Leontiadis, MD, PhD on behalf of the CAG Clinical Affairs Health Canada have recently provided an information update on proton pump inhibitor (PPI) therapy and risk of fracture in April 2013 (1) stating “Several scientific studies suggest that PPI therapy may be associated with a small increased risk for fractures of the hip, wrist, or spine related to osteoporosis, a disease resulting

2013 CPG Infobase

75. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. (Full text)

Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Treatment with proton pump inhibitors (PPIs) improves clinical outcomes in patients with peptic ulcer bleeding. However, the optimal dose and route of administration of PPIs remains controversial.To evaluate the efficacy of different regimens of PPIs in the management of acute peptic ulcer bleeding using evidence from direct comparison randomized controlled trials (RCTs).We specifically intended

2013 Cochrane PubMed

76. Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis

Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

77. Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients: A Systematic Review and Meta-Analysis (PubMed)

Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients: A Systematic Review and Meta-Analysis Critically ill patients may develop bleeding caused by stress ulceration. Acid suppression is commonly prescribed for patients at risk of stress ulcer bleeding. Whether proton pump inhibitors are more effective than histamine 2 receptor antagonists is unclear.To determine the efficacy and safety of proton pump inhibitors vs. histamine 2 (...) receptor antagonists for the prevention of upper gastrointestinal bleeding in the ICU.We searched Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, ACPJC, CINHAL, online trials registries (clinicaltrials.gov, ISRCTN Register, WHO ICTRP), conference proceedings databases, and reference lists of relevant articles.Randomized controlled parallel group trials comparing proton pump inhibitors to histamine 2 receptor antagonists for the prevention of upper gastrointestinal bleeding

2013 EvidenceUpdates

78. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis

Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

79. The Efficacy of Proton Pump Inhibitor Therapy for Treating Laryngopharyngeal Reflux: A Systematic Review

The Efficacy of Proton Pump Inhibitor Therapy for Treating Laryngopharyngeal Reflux: A Systematic Review "The Efficacy of Proton Pump Inhibitor Therapy for Treating Laryngophar" by Wendy Kellam < > > > > > Title Author Date of Graduation Summer 8-10-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Laryngopharyngeal reflux (LPR) is the backflow of stomach contents into the throat. The current standard of care is to treat (...) patients with a proton pump inhibitor (PPI) twice daily for up to 6 months or longer. Two meta-analyses were completed in 2006 and found no evidence PPI therapy is better than placebo for chronic laryngitis. Since that time new tools have been created to measure outcomes in this field of research, the Reflux Finding Score (RFS) and Reflux Symptom Index (RSI). Using these standardized measures are researchers able to demonstrate PPI therapy is efficacious in the treatment of LPR? Method: An exhaustive

2013 Pacific University EBM Capstone Project

80. Cohort study: Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study

Cohort study: Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study Article Text Aetiology Cohort study Proton pump inhibitors do

2013 Evidence-Based Medicine (Requires free registration)